Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
about
sameAs
Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesionPrognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysisHBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literatureBiliary tract cancers: SEOM clinical guidelinesOncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in miceTwo classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.A case of distal extrahepatic cholangiocarcinoma with two positive resection margins.Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.PD-L1 expression in extrahepatic cholangiocarcinoma.Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression.Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma.Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients.Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture.Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital.Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis.Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma.Cholangiocarcinoma: from risk to prevention?The Curious Case of Cholangiocarcinoma: Opportunities for Environmental Health Scientists to Learn about a Complex Disease
P2860
Q30234532-52770CF5-348D-4314-88CD-20608F49A48EQ33593231-0879CD8C-FF5A-4C5A-BBB7-D9EB9A8C85C8Q33829684-60A56096-9EDD-4DDA-91F4-10144B4E5C7AQ36052356-1430C652-EF63-4C3A-8FD9-B8C195ECF0ADQ36400234-9778F4F4-12DA-4108-B1F4-C443BF0F494DQ36501683-58C653E6-223B-4FDA-9A2A-BB5CE6A503EDQ37269146-3001B36A-CE73-4095-9218-3DA13CE780EDQ37407304-0B34CAC9-25B8-484F-AF75-29E737797B49Q37716471-A28E5000-04B6-4BBF-9F5F-FF44D3F1F099Q38728836-05DE3A10-6C8B-4DEB-93AE-8337681A0D7FQ38754853-C1793D8B-C201-4233-AAAF-DCB33D53AB68Q38905922-9E0FBA9E-6C19-4083-A99D-C1F7096222F7Q39025911-D6DF20C8-E976-4876-A398-323AA9DE68DEQ40151513-F17BE4F0-C1E1-41DC-9D92-39768C11D0A9Q47403256-80B436E2-5566-4BEC-97F8-7BC0056E28D9Q47645620-BF05265C-C759-45D4-B0C7-7C6C5018DE43Q48149064-ECA2ACF6-4DE2-42EE-B4B3-2E4C1549D107Q54989916-B0FE6066-91EB-47FC-9972-4113BC89A431Q55248371-AB744D2C-607D-41A5-8891-3B2D43AB021DQ55260649-C502DDCA-F0F5-47F9-B696-AC3F40ABD56EQ55363407-B601CEE8-9D83-4C97-9FC1-36D670C4E39FQ56964612-E1C7440B-D27E-4362-8E18-A569FC3A9843Q58792806-B427A901-C290-470A-A32C-01B8AEAC8D17
P2860
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@ast
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@en
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@nl
type
label
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@ast
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@en
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@nl
prefLabel
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@ast
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@en
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
@en
P2093
Andrea Farioli
Giovanni Brandi
Simona Tavolari
P2860
P304
14744-14753
P3181
P356
10.18632/ONCOTARGET.4539
P407
P5008
P577
2015-06-20T00:00:00Z